Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
The surge of oncologic tissue-agnostic therapies: a precision medicine maneuver!
Aparna Lanka, Consultant, IQVIA Pipeline Intelligence
Vipresha Jain, Analyst, IQVIA Pipeline Intelligence
Jul 08, 2019
  • Blogs
  • The surge of oncologic tissue-agnostic therapies: a precision medicine maneuver!

Introduction

Cancer care has advanced towards a new wave of personalization being tailor-made for an individual based on genomic makeup, ending the ‘one-size-fits-all’ approach of traditional medicine. Tissue/tumor/site-agnostic therapies are an important subdivision of personalized medicine. These therapies target specific genomic biomarker shared across different types of cancers regardless of their location and histology, unlike the therapies that target specific biomarker-positive tumors restricted to a specific organ or tissue. By eliminating the tissue restriction of tumor type, this new-age concept has revolutionized precision medicine.

The progress

Traditionally oncologists have treated patients with drugs based on the organ or tissue where the tumors originated. With advances in molecular diagnostics, it was anticipated that molecularly targeted treatments would be effective against a spectrum of biomarker-defined tumor types, rather than being restricted to the site of tumor origin. However, the molecular and cellular heterogeneity of tumor sites posed unique circumstances with regards to the population of patients who might benefit from it. The targeted therapies being developed could be directed towards specific genomic alterations in EGFR, ALK, ROS1, HER2, KIT, BRAF and germline BRCA1/2, but only for specific tumor types (e.g. ALK inhibitors in lung cancer with EML4-ALk fusion and HER2/neu blockage in HER2/neu-positive breast cancer). Equipped with the advent of immunotherapies and the discovery of tumor neoantigens, combined with the advances of high-throughput genomic sequencing, tissue-agnostic cancer drug development came to fruition.

In 2012, scientists at Johns Hopkins University (USA) theorized that tumors harboring alterations in mismatch repair genes producing large numbers of neoantigens that can elicit immune responses, should be particularly sensitive to immune checkpoint inhibitors that recognize these responses and stimulate a T-cell response. Their successful research paved way for the emergence of tissue-agnostic cancer therapies.

The biomarker targets of tissue-agnostic therapies

Some selected actionable cancer gene aberrations that are agnostic to tissue types are depicted in Figure 1.

Challenges

Tumor-agnostic therapies challenge the existing diagnostic, regulatory and HTA frameworks, and market entry pathways. Patient screening may also be a hurdle as universal testing for rare biomarkers may not be covered through insurance due to high costs. These drugs also come with an expensive price tag. Testing of these therapies in a basket trial may be a long process due to recruitment hurdles owing to small sample sizes. Furthermore, a histology-independent development model is not going to universally work for all tumor-agnostic therapies – the same level of antitumor activity might not occur across different malignancies. Therefore, tumor-agnostic therapies cannot entirely replace conventional histology-based treatments.

The road to future

As we embrace a biomarker-based approach, the breadth and depth of precision medicine is gaining the much-deserved spotlight and is being recurrently highlighted  in reputable cancer conferences in recent years – the American Society of Clinical Oncology (ASCO) annual meeting 2018 explored the theme of ‘Delivering Discoveries: Expanding the Reach of Precision Medicine’ and the American Association for Cancer Research (AACR) annual meeting 2019 explored the theme of ‘Individualized Patient Care’. Basket trials, such as NCI-MATCH and NCI-COG Pediatric MATCH, that recruit patients of several tumor types with rare mutations to study responses across different biomarkers, are being conducted to investigate potential therapies and to provide data to expand the potential population of patients who can respond to a biomarker target. Patient recruitment in basket trials can be informed by employing cutting-edge comprehensive diagnostic panels that use next generation sequencing for genomic profiling.  Collaboration among regulatory and HTA bodies, clinical investigators, physicians, pharma companies and patient groups is critical in bringing more tissue-agnostic therapies to bedside.

Register to the INNsight Newsletter for regular patent, pipeline and conference updates.

Related solutions

Oncology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us